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Abstract
Background: Discrepancies between information in conference abstracts and full publications describing the same
randomized controlled trial have been reported. The association between author conflicts of interest and the
publication of randomized controlled trials is unclear.
The objective of this study was to use randomized controlled trials in ophthalmology to evaluate (1) the agreement in
the reported main outcome results by comparing abstracts and corresponding publications and (2) the association
between the author conflicts of interest and publication of the results presented in the abstracts.
Methods: We considered abstracts describing results of randomized controlled trials presented at the 2001–2004
Association for Research in Vision and Ophthalmology conferences as eligible for our study. Through electronic searching
and by emailing abstract authors, we identified the earliest publication (journal article) containing results of each abstract’s
main outcome through November 2013. We categorized the discordance between the main outcome results in the
abstract and its paired publication as qualitative (a difference in the direction of the estimated effect) or as quantitative.
We used the Association for Research in Vision and Ophthalmology categories for conflicts of interest: financial interest,
employee of business with interest, consultant to business with interest, inventor/developer with patent, and receiving≥
1 gift from industry in the past year. We calculated the relative risks (RRs) of publication associated with the categories of
conflicts of interest for abstracts with results that were statistically significant, not statistically significant, or not reported.
Results: We included 513 abstracts, 230 (44.8 %) of which reached publication. Among the 86 pairs with the same
main outcome domain at the same time point, 47 pairs (54.7 %) had discordant results: qualitative discordance in 7
pairs and quantitative discordance in 40 pairs. Quantitative discordance was indicated as < 10, 10–20, > 20 %, and
unclear in 14, 5, 14, and 7 pairs, respectively. First authors reporting of one or more conflicts of interest was associated
with a greater likelihood of publication (RR = 1.31; 95 % CI = 1.04 to 1.64) and a shorter time-to-publication (log-rank
p = 0.026). First author conflicts of interests that were associated with publication were financial support (RR = 1.50;
95 % CI = 1.19 to 1.90) and one or more gifts (RR = 1.42; 95 % CI = 1.05 to 1.92). The association between conflicts of
interest and publication remained, irrespective of the statistical significance of the results.
Conclusions: More than half the abstract/publication pairs exhibited some amount of discordance in the main
outcome results, calling into question the dependability of conference abstracts. Regardless of the main outcome
results, the conflicts of interests of the abstract’s first author were associated with publication.
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Background
The results of randomized controlled trials (RCTs) pre-
sented at conferences and reported in conference ab-
stracts (“abstracts”) influence clinicians, patients, and
systematic reviewers and can affect clinical decisions
when abstracts are the sole sources of reported results
[1–3]. In addition, when abstracts are not published in
full, systematic reviewers are recommended to include
the results reported in abstracts [4–7].
RCT information reported in conference abstracts, how-
ever, may not be reliable. Abstracts do not typically
undergo full peer review, may contain preliminary results,
and may contain insufficient information to assess meth-
odological quality [8]. Indeed, differences between ab-
stracts and other sources have been found for results
of RCTs [9, 10]. In ophthalmology, 34 % of primary
outcomes in abstracts had not been specified as such
in ClinicalTrials.gov, a major clinical trials registry
[11]. In other fields, results have been shown to be
discrepant between abstracts and full publications
(“publications”) from the same RCT. Studies in ortho-
pedics [12, 13], cardiology [14], pediatrics [15],
pediatric surgery [1], and infectious disease [16] have
shown that 40 to 60 % of reports describing RCTs
present discrepant results in abstracts and publica-
tions. In ophthalmology, however, the extent of dis-
crepancies in the results reported in abstracts and
publications is unknown. Additionally, interim or final
study results may be reported in abstracts [17], and
sometimes, whether the RCT being reported has been
completed is unclear. In addition, publishing often is
not a goal of abstract authors [18].
Across a number of fields, published RCTs may be
fundamentally different from RCTs reported only in
abstracts. For example, abstracts describing statisti-
cally significant effect estimates or those with positive
results have been shown to be more likely to be pub-
lished in full [19–21]. Industry funding also has been
shown to be positively associated with publication
[20], and among published RCTs, industry funding is
associated with study results that favor the active
treatment being evaluated [22–25]. The impact of
study investigator conflicts of interest (COIs) on pu-
blication is less clear, however. COIs are conditions in
which professional judgment concerning a primary
interest (e.g., patient welfare or research validity)
might be unduly influenced by a secondary interest
(e.g., financial gain) [26, 27].
Objectives
We studied RCTs in ophthalmology to evaluate (1) the
agreement in the reported main outcome results be-
tween abstracts and corresponding publications and (2)
the association between author COIs and the publication
of the results presented in the abstracts.
Methods
Abstracts
Abstracts were eligible if they described RCT results and
were presented at the 2001–2004 conferences of the As-
sociation for Research in Vision and Ophthalmology
(ARVO). For 2001, we used the printed ARVO abstract
book, and for 2002–2004, we used compact discs (CDs)
of the ARVO abstracts. We included RCTs addressing
any intervention for patients with any clinical condition
or involving healthy volunteers.
Publications
Using two strategies, we searched for the earliest publi-
cation (journal article) containing results of each ab-
stract’s main outcome:
1. We searched Medline, Cochrane Central Register of
Controlled Trials (CENTRAL), Excerpta Medica
Database (EMBASE), Latin American and Caribbean
Health Sciences Literature (LILACS), Web of
Science, and Scopus. We searched by all abstract
authors and unique search terms from the abstract.
We searched from 2 years before the abstract was
presented through 2013.
2. When no publication was identified, we emailed the
abstract’s authors to inquire if the RCT had been
published.
Data extraction
For each abstract and publication, two investigators inde-
pendently extracted information on author characteristics,
study design, participants, interventions, comparisons,
and all outcomes. We resolved discrepancies through
discussion.
Classifying statistical significance
For the main outcome (see Table 1 for how this was de-
fined) in each abstract and publication, we extracted all
reported data at the last available time point. We
Table 1 How we identified the main outcome in each abstract
and publication
1. If only one primary outcome was specified, we selected that
outcome as the main outcome.
2. If more than one primary outcome was specified, we selected the
first outcome reported in the “Results” section as the main outcome.
3. If no primary outcome was specified, we selected the outcome
mentioned in the “Title” or “Objective” as the main outcome.
4. If no primary outcome was specified and no outcome was
mentioned in the “Title” or “Objective,” we selected the first outcome
reported in the “Results” section as the main outcome.
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considered results for the main outcome as “statistically
significant” if the effect estimate, 95 % confidence inter-
val, or p value indicated statistical significance at the 5 %
level for at least one reported between-arm comparison
for the main outcome and “not statistically significant” if
no statistical significance at the 5 % level was obtained
for any reported between-arm comparison for the main
outcome. When insufficient data were reported, or when
the authors stated that the results were statistically signifi-
cant without reporting the effect estimate, 95 % con-
fidence interval, or p value, we classified the
statistical significance of the results as “not re-
ported.” While our primary analysis focused on the
“main” outcome, we also evaluated the statistical sig-
nificance for “any” (at least one) outcome.
Because many abstracts did not report statistical
significance of the main outcome, we evaluated the
association between statistical significance and publi-
cation under five different hypothetical assumptions.
We assumed the results were statistically significant
in none (assumption 1) and in 25 % (assumption 2),
50 % (assumption 3), 75 % (assumption 4), and 100 %
(assumption 5) of those abstracts. For assumptions 2,
3, and 4, we used the “runiform” command in
STATA© to select abstracts as statistically significant.
Agreement in the main outcome results between
abstracts and corresponding publications
For each abstract/publication pair, we determined whether
the main outcome domain was the same and reported at
the same time point in both documents. For each pair in
which the main outcome domain and time point were the
same and statistical significance was reported, we evaluated
whether the results agreed.
We classified discordance as either qualitative or quanti-
tative. We defined “qualitative discordance” as a difference
in the direction of the effect estimate or the statistical sig-
nificance of the p value. For example, if the effect estimate/
p value was statistically significant (p < 0.05) in the abstract
and not statistically significant in the publication (or vice
versa), or if one intervention arm was statistically signifi-
cantly favored in the abstract and another arm was statisti-
cally significantly favored in the publication, this would
indicate qualitative discordance. We defined “quantitative
discordance” of an effect estimate for the main outcome as
any difference in the magnitude but not in the direction,
when comparing the abstract with the publication. Specific-
ally, for each abstract/publication pair, we calculated the
percent difference in the reported effect estimates as
follows:
This equation for percent difference was applied to
all effect estimates (e.g., the relative risk, odds ratio,
and hazard ratio). We categorized the quantitative
discordance based on the percent differences: < 10,
10 to 20, and > 20 %. When effect estimates were re-
ported in both abstract and publication, we used the
reported effect estimates to make the comparison.
When effect estimates were not reported, but suffi-
cient information was reported to calculate them, we
did so. When only p values were reported (without
effect estimates or sufficient information to calculate
effect estimates), any quantitative difference in the p
value, without a difference in the direction of statis-
tical significance (at the 5 % level), also qualified as
quantitative discordance; we categorized these as
“quantitative discordance – amount unclear.”
Author COIs
We adopted the following COI classification system
used by ARVO in 2001–2004: (1) financial support,
(2) personal financial interest, (3) employment by a
business with interest, (4) consultancy to a business
with interest, (5) inventor/developer with patent, and
(6) receiving at least one gift from a business with
interest in the past year (Additional file 1: Table S1).
For 2001, the COI data were presented only as aggre-
gated information for the entire author team. From
2002, ARVO required disclosure of COI separately for
each author, and we extracted the disclosed COI for
each author.
Statistical analysis
To evaluate the agreement in main outcome results
in the abstract/publication pairs, we calculated the
frequency with which each form of discordance
occurred.
In model 1, we estimated the relative risk (RR) of pub-
lication using log-binomial models to examine the asso-
ciation between the COI and publication. In model 2, we
examined whether there was an interaction between sta-
tistically significant results for the main outcome as re-
ported in the abstract and the association between the
COI and publication. Model 2 contained terms for the
interaction between the COI and (1) whether the statis-
tical significance for the main outcome was reported in
the abstract and (2) whether the main outcome in the
abstract was statistically significant. We ran models 1
and 2 separately for at least one COI and for each spe-
cific COI for the first author, last author, and any author.
Percent Difference ¼ Effect estimate reported in abstract−Effect estimate reported in publication
Effect estimate reported in publication
 100
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We plotted Kaplan-Meier curves depicting the cumula-
tive probability of publication of abstracts over time (in
months). We conducted log-rank significance tests of dif-
ferences in the probability of publication at any time point
during follow-up [28]. We considered abstracts published
before or at the time of presentation at the conference as
being published within 1 month of presentation.
Results
Specification of the main outcome in the abstracts
For the years 2001–2004, 513/20,721 (2.6 %) abstracts pre-
sented at ARVO described RCT results (Additional file 2:
Figure S1). We classified the only stated primary outcome
as the main outcome for 49 abstracts (9.6 %), the outcome
mentioned in the “Title” or “Objective” for 318 abstracts
(62.0 %), and the outcome reported first in the “Results”
section for the remaining 146 abstracts (28.5 %).
Agreement in the main outcome results between the
abstracts and corresponding publications
Of the 513 abstracts, 230 (44.8 %) were published
(Table 2). The median time from the conference presen-
tation to publication was 18 months (interquartile range
(IQR) = 11 to 33, range = 1 to 90) (Fig. 1a). The main
outcome domain was the same for 190/230 (83.6 %) ab-
stract/publication pairs (Additional file 2: Figure S1). For
Table 2 Characteristics, main outcome results (overall and by whether or not the randomized controlled trial (RCT) described in the
abstract was published), and the association with publication of the abstracts of RCTs presented at the Association for Research in
Vision and Ophthalmology (ARVO) conferences during the years 2001–2004
Characteristics All abstracts
(N = 513)
Abstracts of unpublished
RCTs (N = 283)
Abstracts of published
RCTs (N = 230)
Relative risks
(RR) (95 % CI)
n (%**) n (%**) n (%**)
Characteristics of the RCTs
Funding
Not reported 241 (47.0) 137 (48.4) 104 (45.2)
Reported 272 (53.0) 146 (51.6) 126 (54.8)
At least one funding
source
158 (58.1) 73 (50.0) 85 (67.5) 1.32 (1.09–1.60)
Industry
(pharmaceutical or
other)*
56 (20.7) 22 (15.1) 34 (27.0) 1.42 (1.12–1.79)
Government* 71 (26.1) 31 (21.2) 40 (31.8) 1.31 (1.04–1.65)
Other* 59 (21.7) 30 (20.6) 29 (23.0) 1.11 (0.84–1.47)
No funding 114 (41.9) 73 (50.0) 41 (32.5) 0.76 (0.58–0.99)
Number of centers
Not reported 361 (70.4) 208 (73.5) 153 (66.5) Ref
Reported 152 (29.6) 75 (26.5) 77 (33.5) 1.20 (0.98–1.46)
Single center 46 (30.3) 31 (41.3) 15 (19.5) Ref
Multicenter 106 (69.7) 44 (58.7) 62 (80.5) 1.79 (1.15–2.80)
Presentation at ARVO
Poster 418 (81.5) 239 (84.5) 179 (77.8) Ref
Oral 95 (18.5) 44 (15.5) 51 (22.2) 1.25 (1.01–1.56)
Main outcome results
Main outcome -
Statistical significance
Not reported 285 (55.6) 178 (63.9) 107 (46.5) Ref
Reported 228 (44.4) 105 (37.1) 123 (53.5) 1.44 (1.19–1.74)
Not statistically
significant
111 (48.7) 52 (49.5) 59 (48.0) Ref
Statistically significant 117 (51.3) 53 (50.5) 64 (52.0) 0.97 (0.76–1.24)
* More than one option could apply to each abstract
** Percentages are column percentages. Percentages in the shaded rows are calculated using as the denominator number of abstracts reporting
that characteristic
Data (RRs and 95 % CIs) reported in bold text are statistically significant at the 5 % level
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19 of the 190 pairs (10.0 %), we ascertained that the
RCT was ongoing (still following participants) when the
abstract was written.
The main outcome agreed, and the results were reported
in both the abstract and the publication at the same time
point for 86/190 pairs. The results exactly agreed for 39/86
pairs (45.3 %), and discordance was noted for 47/86 pairs
(54.7 %): quantitative discordance in 40 pairs and qualita-
tive discordance in 7 pairs (Fig. 2a). If we defined agreement
as exact agreement or < 10 % of discordance, discordance
was observed for 33 pairs (38.4 %) (Fig. 2b).
RCT funding characteristics and publication
The proportions of abstracts reporting industry, govern-
ment, and other funding were similar (20.7, 26.1, and
21.7 %, respectively) (Table 2). The abstracts reporting
no funding were less likely to be published compared
with all other abstracts (RR = 0.76; 95 % CI = 0.58 to
0.99), whereas abstracts reporting industry and go-
vernment funding were more likely to be published.
These findings are reflected in the shorter time-to-
publication for the funded RCTs compared with all
other RCTs (log-rank p = 0.021) (Fig. 1b).
Statistical significance of results and publication
The statistical significance of the results for the main out-
come was reported in 228/513 (44.4 %) abstracts (Table 2).
The results were statistically significant in 117 of the 228
abstracts (51.3 %), and most findings (102/117, 87.2 %) fa-
vored the experimental arm. Abstracts reporting statistical
significance for the main outcome were more likely to be
published (123/228) than abstracts not reporting it (107/
285) (RR = 1.44; 95 % CI = 1.19 to 1.74), and were published
sooner (log-rank p < 0.001) (Fig. 1d). Among the 228 ab-
stracts reporting statistical significance for the main out-
come, no association was observed between the results
being statistically significant and publication (RR = 0.97;
95 % CI = 0.76 to 1.24) or time-to-publication (Fig. 1e).
Abstracts reporting statistical significance for at least
one outcome were more likely to be published (135/249)
than abstracts not reporting it for any outcome (95/264)
(RR = 1.51; 95 % CI = 1.24 to 1.84). Among the 249 ab-
stracts reporting statistical significance for at least one
outcome, no association was observed between the re-
sults being statistically significant and publication (RR
= 1.06; 95 % CI = 0.84–1.35).
Assumption-based analyses of statistical significance of
results and publication
Many abstracts (285/513, 55.6 %) did not report statis-
tical significance of results for the main outcome. When
we assumed that the results were not statistically signifi-
cant in the abstracts that did not mention statistical sig-
nificance (assumption 1) or in a randomly selected 25 %
of the abstracts (assumption 2), the abstracts with
significant results were more likely to be published
(RR = 1.31, 95 % CI = 1.07 to 1.60 and RR = 1.28,
95 % CI = 1.06–1.55, respectively) (Additional file 3:
Figure S2). An inverse association was observed
when we assumed the results were statistically sig-
nificant in 100 % of those abstracts (RR = 0.80; 95 %
CI = 0.65 to 0.99) (assumption 5).
Abstract author COIs
Among the 230 pairs of abstracts and publications, at
least one difference in authorship between the abstract
and publication was observed in 202 pairs (87.8 %)
(Additional file 4: Table S2). At least one author re-
ported one or more COI 34.5 % of the time (177/513 ab-
stracts) (Table 3). Compared with last authors, first
authors more often reported financial support (18.8 vs.
9.0 %) and less often reported employment by a business
with interest (4.3 vs. 13.9 %).
COI and publication – overall and interaction analyses
(models 1 and 2)
Abstracts with the first author reporting at least one COI
had a greater likelihood of publication (RR = 1.31; 95 % CI
= 1.04 to 1.64) (Table 4) and shorter time-to-publication
(log-rank p = 0.026) (Fig. 1f) compared with all other
abstracts. A positive association between COIs and
publication was not observed for the last author or for any
author, however (Table 4 and Fig. 1g and h). Abstracts with
the first author reporting financial support from industry
(RR = 1.50; 95 % CI = 1.19 to 1.90) or at least one gift from
industry within the past year (RR = 1.42; 95 % CI = 1.05 to
1.92) were more likely to be published compared with other
abstracts. Results from models 1 and 2 were similar, and
none of the interaction terms was statistically significant
(Table 4).
Discussion
In this longitudinal study of 513 abstracts of RCTs pre-
sented at ARVO, 230 (44.8 %) of which were published,
we demonstrated either qualitative or quantitative dis-
cordance in results for the same main outcome reported
at the same time point for 55 % of the 86 abstract/publi-
cation pairs. Abstracts with first authors reporting at
least one COI were 31 % more likely to be published
and were published sooner, compared with all other ab-
stracts, irrespective of the statistical significance of the
result for the main outcome in the abstract.
Dependability of abstracts
We are concerned about the discordance between the
results presented in the abstracts and publications, a dis-
cordance now reported for various fields. Our finding in
ophthalmology is consistent with previous research
Saldanha et al. Trials  (2016) 17:213 Page 5 of 13
N = 513 abstracts
P
ro
po
rt
io
n 
of
 a
bs
tr
ac
ts
 p
ub
lis
he
d 
in
 fu
ll
n = 158 abstracts
P
ro
po
rt
io
n 
of
 a
bs
tr
ac
ts
 p
ub
lis
he
d 
in
 fu
ll
N = 513 abstracts
n = 241 abstracts
n = 114 abstracts
Log-rank p=0.021
n = 106 abstracts
P
ro
po
rt
io
n 
of
 a
bs
tr
ac
ts
 p
ub
lis
he
d 
in
 fu
ll
N = 513 abstracts
n = 361 abstracts
n =   46 abstracts
Log-rank p=0.006
n = 228 abstracts
P
ro
po
rt
io
n 
of
 a
bs
tr
ac
ts
 p
ub
lis
he
d 
in
 fu
ll
N = 513 abstracts
n = 285 abstracts
Log-rank p<0.001
n = 111 abstracts
Pr
op
or
o
n 
of
 a
bs
tr
ac
ts
 p
ub
lis
he
d 
in
 fu
ll
N = 228 abstracts
n = 117 abstracts
Log-rank p=0.881
n = 132 abstracts
P
ro
po
rt
io
n 
of
 a
bs
tr
ac
ts
 p
ub
lis
he
d 
in
 fu
ll
N = 400 abstracts
n = 268 abstracts
Log-rank p=0.026
n = 103 abstracts
P
ro
po
rt
io
n 
of
 a
bs
tr
ac
ts
 p
ub
lis
he
d 
in
 fu
ll
N = 400 abstracts
n = 297 abstracts
Log-rank p=0.746
n = 177 abstracts
P
ro
po
rt
io
n 
of
 a
bs
tr
ac
ts
 p
ub
lis
he
d 
in
 fu
ll
N = 513 abstracts
n = 336 abstracts
Log-rank p=0.213
a b
c d
e f
g h
Fig. 1 (See legend on next page.)
Saldanha et al. Trials  (2016) 17:213 Page 6 of 13
showing discrepancies in results for 40 to 60 % of pairs
of abstracts and publications in various fields [1, 12–16].
In our study, when the same main outcome was re-
ported at the same time point, 7/86 pairs (8.1 %) re-
ported qualitatively different results for the same
outcome in the two reports. This implies that if a deci-
sion maker were using the results of an RCT to make a
treatment decision, approximately one in 12 decisions
would be different, depending on whether the decision
was based on the abstract or on the publication. More-
over, our finding that some form of discordance is more
common than agreement was based on the abstracts of
published RCTs; abstracts of unpublished RCTs might
be even less dependable.
Almost half the pairs reported quantitatively different
results for the same main outcome. A small discrepancy
in RR estimates reported in an abstract/publication pair
might not be considered meaningful for an individual
trial but could impact meta-analytic effect estimates.
While a comparison of reported findings would not be
appropriate when the abstract presented preliminary
findings and the publication the final results, in our
assessment, this was the case only 18.3 % of the time
(19/104 pairs).
The current existence of discordance mandates that,
when only an abstract is available, systematic reviewers
should be cautious about including abstract results, run-
ning appropriate sensitivity analyses with and without
the information [7, 8]. Second, when both the abstract
and publication are available and the data for an out-
come are discordant, the authors should be contacted
for clarification.
One potential reason for results of a given outcome to
be discrepant when comparing an abstract and a publi-
cation is that the way the analysis was conducted may
differ between the two. For example, the analysis con-
ducted for data reported in the abstract might have been
preliminary, and changes to the statistical model may
have occurred when the analysis was conducted for data
reported in the publication, or the analysis reported in
the publication might have been post-hoc. Although we
did not examine for the presence of such differences in
Fig. 2 The amount of agreement in the main outcome results in 86 pairs of conference abstracts and full publications. Exact agreement (green),
qualitative discordance (yellow), and various categories of quantitative discordance (blue) are depicted under two different definitions of
agreement – exact agreement (a, left) and exact agreement or < 10 % discordance (b, right)
(See figure on previous page.)
Fig. 1 Kaplan-Meier plots showing time to full publication of abstracts of randomized controlled trials (RCTs) presented at the ARVO conference during
the years 2001–2004, overall and by various study characteristics, author characteristics, and statistical significance of results for the main outcome. a All
abstracts. b By study funding. Blue = funded; green = not reported; maroon = not funded. c By number of centers. Blue = multicenter; green = not
reported; maroon = single center. d By reporting of statistical significance of results for the main outcome. Blue = reported; maroon = not reported. e
By statistical significance of results for the main outcome. Maroon = statistically significant; blue = not statistically significant. f By whether or not the
“first author” reported at least one conflict of interest (COI). Maroon = at least one COI; blue = no COI. g By whether or not the “last author” reported at
least one COI. Maroon = at least one COI; blue = no COI or not applicable/abstract had only one author. h By whether or not ANY AUTHOR reported
at least one COI. Maroon = at least one COI; blue = no COI
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Table 3 Author characteristics of abstracts of randomized controlled trials (RCTs) presented at the Association for Research in Vision
and Ophthalmology (ARVO) conferences during the years 2001–2004, overall and by whether or not the RCT described in the
abstract was published
Characteristics All abstracts n (%**) Abstracts of unpublished RCTs n (%**) Abstracts of published RCTs n (%**)
Characteristics of first authors
Primary affiliation N = 513 N = 283 N = 230
Not reported 8 (1.6) 7 (2.5) 1 (0.4)
Reported 505 (98.4) 276 (97.5) 229 (99.6)
Academic 311 (61.6) 156 (56.5) 155 (67.7)
Industry 31 (6.1) 18 (6.5) 13 (5.7)
Hospital/Clinic 123 (24.4) 76 (27.5) 47 (20.5)
Other 40 (7.9) 26 (9.4) 14 (6.1)
Conflicts of interest (COI) (years 2002–2004 only) N = 400 N = 229 N = 171
Not reported 0 (0.0) 0 (0.0) 0 (0.0)
Reported 400 (100.0) 229 (100.0) 171 (100.0)
At least one COI 132 (33.0) 65 (28.4) 67 (39.2)
Financial support* 75 (18.8) 31 (13.5) 44 (25.7)
Personal finance interest* 4 (1.0) 2 (0.9) 2 (1.2)
Employee of business with interest* 17 (4.3) 13 (5.7) 4 (2.3)
Consultant of business with interest* 43 (10.8) 23 (10.0) 20 (11.7)
Inventor/developer with patent* 8 (2.0) 5 (2.2) 3 (1.8)
Received gifts within the past year* 36 (9.0) 15 (6.6) 21 (12.3)
No COI 268 (67.0) 164 (71.6) 104 (60.8)
Characteristics of last authors
Primary affiliation N = 513 N = 283 N = 230
Not applicable (abstract had one author) 28 (5.5) 8 (2.8) 20 (8.7)
Not reported 8 (1.6) 7 (2.5) 1 (0.4)
Reported 477 (93.0) 268 (94.7) 209 (90.9)
Academic 258 (54.1) 140 (52.2) 118 (56.5)
Industry 85 (17.8) 39 (13.8) 46 (22.0)
Hospital/Clinic 106 (22.2) 69 (25.8) 37 (17.7)
Other 28 (5.9) 20 (7.1) 8 (3.8)
COI (years 2002-2004 only) N = 400 N = 229 N = 171
Not applicable (abstract had one author) 21 (5.3) 8 (3.5) 13 (7.6)
Not reported 12 (3.0) 6 (2.6) 6 (3.5)
Reported 367 (91.7) 215 (93.9) 152 (88.9)
At least one COI 103 (28.1) 56 (26.1) 39 (25.7)
Financial support* 33 (9.0) 21 (9.8) 12 (7.9)
Personal finance interest* 1 (0.3) 1 (0.5) 0 (0.0)
Employee of business with interest* 51 (13.9) 28 (13.0) 23 (15.1)
Consultant of business with interest* 18 (4.9) 8 (3.7) 10 (5.9)
Inventor/developer with patent* 5 (1.4) 3 (1.4) 2 (1.2)
Received gifts within the past year* 14 (3.8) 7 (3.3) 7 (4.6)
No COI 264 (71.9) 159 (74.0) 113 (74.3)
COIs of any author
COI N = 513 N = 283 N = 230
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the analyses of our sample, authors of ARVO abstracts
have been reported to present results based on analyses
not originally planned [11].
Suggestions to mitigate the impact of discordance
between results presented in abstracts and publications
We have two specific suggestions for mitigating the im-
pact of discordance between results presented in ab-
stracts and publications. First, the scientific community
should be made aware when the results presented in an
abstract are preliminary. This could be achieved through
the addition of a checkbox or other simple feature in the
abstract submission system that authors would use to in-
dicate abstracts with preliminary results. Readers of ab-
stracts can thus be alerted to the possibility that a newer
version of the results might be available elsewhere, and
at the very least, the reader can be cautioned about the
possible nonreliability of the results. Second, when au-
thors submit manuscripts to journals, authors should be
required to indicate whether the results have been previ-
ously presented at a conference, and if so, authors
should be required to upload the abstract(s). The sub-
mitted abstract(s) should be part of the materials pro-
vided to the peer reviewers and editors.
Low proportion of abstracts published
Our study documents an even lower proportion of full
publication of results of RCTs presented in abstracts
(44.8 %) than has been previously shown in a Cochrane
review (63.1 %) [20]. This lower proportion is despite
our study having a longer duration of follow up than the
studies in the Cochrane review (up to 146 months versus
up to 108 months, respectively).
We do not know of a reason inherent to ophtha-
lmology as a specific field that might explain the low
proportion of published abstracts in our sample. One
possibility is that ARVO organizers encourage the pres-
entation of works in progress, and ARVO has a very
high proportion of submitted abstracts that are accepted.
It is possible that few authors are aiming to publish in
full [18]. For example, junior investigators may present
abstracts as a means to cover travel expenses to the con-
ference. Preparation of abstracts and presentation at a
conference may also be encouraged as educational expe-
riences, especially in academic institutions. However, the
failure to publish results of RCTs should not be swept
under the rug. Because abstracts are often interpreted as
scientific contributions and are an indication of when
reporting biases may exist [20], conference organizers
could require a notation in the abstract submission sys-
tem for authors to indicate when “preliminary” versus
“final” results are being reported.
Failure to publish amounts to research waste and, ar-
guably, to scientific misconduct because it violates the
trust that patients place in scientists when giving in-
formed consent [29–33]. Randomized controlled trials,
as human experiments, must be held to the highest pos-
sible standards, including the full publication of results.
Even when published, the results must be reported ac-
curately. Conference abstracts are a form of scientific
reporting and are considered by clinicians in their clin-
ical decision-making and by systematic reviewers and
guideline developers in their assessment of the body of
evidence.
Significance of results and publication
Although previous research has shown that positive
results are associated with both the publication and
selective reporting of outcomes (publication bias and
outcome reporting bias, respectively), we did not demon-
strate such an association. Considering possible explana-
tions for our findings, it is unlikely that we missed many
Table 3 Author characteristics of abstracts of randomized controlled trials (RCTs) presented at the Association for Research in Vision
and Ophthalmology (ARVO) conferences during the years 2001–2004, overall and by whether or not the RCT described in the
abstract was published (Continued)
Not reported 0 (0.0) 0 (0.0) 0 (0.0)
Reported 513 (100.0) 283 (100.0) 230 (100.0)
At least one COI 177 (34.5) 91 (32.2) 86 (37.4)
Financial support* 99 (19.3) 49 (17.3) 50 (21.7)
Personal finance interest* 6 (1.2) 4 (1.4) 2 (0.9)
Employee of business with interest* 76 (14.8) 40 (14.1) 36 (15.7)
Consultant of business with interest* 66 (12.9) 32 (11.3) 34 (14.8)
Inventor/developer with patent* 13 (2.5) 8 (2.8) 5 (2.2)
Received gifts within the past year* 55 (10.7) 23 (8.1) 32 (13.9)
No COI 336 (65.5) 192 (68.9) 144 (62.6)
* More than one option could apply to each abstract
** Percentages are column percentages. Percentages in shaded rows are calculated with n reported as the denominator
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Table 4 Associations between conflicts of interests (COIs) of authors of abstracts of randomized controlled trials (RCTs) presented at
ARVO conferences during the years 2001–2004 and likelihood of publication of the RCTs, overall model (model 1), and interaction
model, stratified by statistical significance of results for the main outcome (model 2)
Author COIs Model 1** Model 2***
Relative risks (RR)
(95 % CI)
RR (95 % CI) among
abstracts with main
outcome not
statistically significant
RR (95 % CI) among
abstracts with main
outcome statistically
significant
RR (95 % CI) among
abstracts with
statistical significance
of main outcome
not reported
P value of F test of
interaction ****
COIs of first author (years 2002–
2004 only)
N = 400 N = 87 N = 79 N = 234
At least one COI 1.31 (1.04–1.64) 1.13 (0.75–1.72) 1.22 (0.82–1.81) 0.93 (0.63–1.37) 0.73
Financial support* 1.50 (1.19–1.90) 1.44 (0.95–2.17) 1.37 (0.92–2.06) 1.11 (0.74–1.67) 0.75
Personal finance interest* 1.17 (0.44–3.14) – – – -
Employee of business with
interest*
0.54 (0.23–1.28) 0.64 (0.20–2.03) 0.96 (0.04–3.92) 0.21 (0.03–1.38) 0.64
Consultant of business with
interest*
1.10 (0.78–1.55) 0.87 (0.41–1.86) 1.08 (0.58–2.02) 0.86 (0.52–1.40) 0.69
Inventor/developer with
patent*
0.88 (0.36–2.16) – – – -
Received gifts within the
past year*
1.42 (1.05–1.92) 1.47 (0.87–2.46) 1.49 (0.97–2.28) 0.91 (0.52–1.60) 0.92
COIs of last author (years 2002–
2004 only)
N = 400 N = 87 N = 79 N = 234
At least one COI 1.06 (0.82–1.37) 0.93 (0.59–1.47) 1.06 (0.67–1.70) 0.75 (0.50–1.14) 0.85
Financial support* 0.84 (0.53–1.34) 0.73 (0.36–1.50) 0.81 (0.34–1.97) 0.58 (0.25–1.36) 0.96
Personal finance interest* – – – – -
Employee of business with
interest*
1.06 (0.77–1.47) 0.89 (0.45–1.75) 1.08 (0.58–2.02) 0.82 (0.51–1.31) 0.76
Consultant of business with
interest*
1.32 (0.86–2.03) 1.73 (1.13–2.64) 1.56 (0.85–2.87) 0.52 (0.15–1.76) 0.36
Inventor/developer with
patent*
0.94 (0.32–2.75) – – – -
Received gifts within the
past year*
1.18 (0.69–2.01) 1.52 (0.83–2.78) 1.01 (0.25–4.12) 0.76 (0.30–1.91) 0.70
Not reported 1.18 (0.66–2.10) – – – -
Not applicable (abstract had
only one author)
1.00 (0.54–1.86) 1.64 (1.00–2.68) 1.28 (0.72–2.29) 1.03 (0.50–2.12) 0.68
COIs of any author (years 2001–
2004)
N = 513 N = 111 N = 117 N = 285
At least one COI 1.13 (0.93–1.38) 1.01 (0.71–1.45) 1.09 (0.77–1.56) 0.81 (0.59–1.11) 0.72
Financial support* 1.16 (0.93–1.45) 1.02 (0.68–1.53) 1.18 (0.82–1.71) 0.81 (0.55–1.18) 0.83
Personal finance interest* 0.74 (0.24–2.31) – – – -
Employee of business with
interest*
1.07 (0.82–1.38) 0.99 (0.62–1.58) 1.13 (0.66–1.94) 0.80 (0.55–1.17) 0.87
Consultant of business with
interest*
1.18 (0.91–1.52) 0.94 (0.52–1.69) 1.25 (0.86–1.81) 0.83 (0.55–1.25) 0.68
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publications because we employed two strategies to
identify publications and followed the abstracts for 110
to 146 months, comfortably exceeding the time by which
most abstracts are generally published [20, 34]. Two
other possible reasons that may explain what we found
are related to missing information. First, more than half
of the abstracts did not report statistical significance of
results for the main outcome; these abstracts are likely
not a random subset of all the abstracts in our study. In-
deed, when we subjected our data to different assump-
tions for the missing information about statistical
significance, our results were similar to those reported
by others. For example, when we assumed that 25 % of
the abstracts not reporting statistical significance were,
in fact, statistically significant (assumption 2), abstracts
with statistically significant results for the main outcome
were 28 % more likely to be published than abstracts
with main outcome results not statistically significant.
Given that outcomes with positive results are selectively
reported and approximately half of all reported main
outcomes in our study were statistically significant, we
believe it is likely that fewer than half the main out-
comes in abstracts not reporting statistical significance
were actually statistically significant (i.e., assumptions 1
and 2 are reasonable). Indeed, research has shown that
only 43.4 % of unpublished RCTs have statistically sig-
nificant results [20]. Second, only 9.6 % of abstracts in
our study named a “primary” outcome. We developed
an algorithm a priori to determine the main outcome
for the remaining abstracts. Although this algorithm is
likely consistent with how most readers of abstracts de-
termine the most important outcome, our algorithm
might have influenced our findings.
A tradeoff for our study’s strength of a long duration of
follow-up is that the abstracts we examined were pre-
sented at ARVO from 2001 to 2004. This period was prior
to initiatives such as compulsory registration of RCTs.
Mandatory registration of RCTs at ClinicalTrials.gov or at
registries within the WHO International Clinical Trials
Registry Platform (ICTRP) (http://www.who.int/ictrp/en/)
might have mitigated the impact of publication bias and
outcome reporting bias in more recent abstract/publica-
tion pairs. In addition, the CONSORT for Abstracts exten-
sion of the Consolidated Standards of Reporting Trials
(CONSORT) Statement includes clear specification of the
primary outcome as an essential checklist item [35]. Initia-
tives like these might have improved the reporting of out-
comes in more recent abstract/publication pairs. However,
recent studies examining abstracts of RCTs [11, 36–38]
and diagnostic test accuracy studies [39] have indicated
that the reporting of results in abstracts is still suboptimal.
COI and publication
COIs are prevalent in biomedical research. Campbell
and colleagues, in a survey of academic investigators, re-
ported that approximately 28 % of investigators received
financial support, 43 % received gifts, and 33 % had fi-
nancial ties with industry [40]. Similarly, Rochon and
colleagues surveyed 844 biomedical investigators con-
ducting both industry funded and non-industry funded
clinical trials, and asked respondents about adherence to
11 prespecified preferred practices known to promote
the objectivity of research [41]. Adherence to these prac-
tices was reported to be low overall, especially among in-
vestigators conducting industry-funded trials. In a
separate survey of guideline-development panel mem-
bers, Neuman and colleagues reported that 52 % of
panel members declared some form of financial associ-
ation with industry [42].
The potential impact of COIs on the likelihood of
publication appears complex. On one hand, financial
gain might facilitate selective publication of positive
findings [43, 44]. On the other hand, financial gain
might facilitate publication, irrespective of the study re-
sults. Notably, we evaluated COI separately from the
study funding source, which was not reported for almost
half of our abstracts. ARVO did not require disclosure of
study funding during abstract submission.
First authors less often than last authors reported pri-
mary affiliation with industry and employment by a busi-
ness, and more often reported financial support and gifts
Table 4 Associations between conflicts of interests (COIs) of authors of abstracts of randomized controlled trials (RCTs) presented at
ARVO conferences during the years 2001–2004 and likelihood of publication of the RCTs, overall model (model 1), and interaction
model, stratified by statistical significance of results for the main outcome (model 2) (Continued)
Inventor/developer with
patent*
0.86 (0.43–1.71) – – – -
Received gifts within the
past year*
1.35 (1.05–1.72) 1.53 (1.03–2.27) 1.36 (0.90–2.05) 0.95 (0.64–1.42) 0.85
* More than one option could apply to each abstract
** Model 1 – Overall model
*** Model 2 – Interaction model – Results are stratified by whether the main outcome results were not statistically, statistically significant, or not reported
**** F-test of interaction tests the overall statistical significance of the interaction between COI and all interaction terms in model 2. We added two interaction
terms in model 2: (1) whether or not results for the main outcome in the abstract were statistically significant and (2) whether or not statistical significance of
results for the main outcome was reported in the abstract
Data (RRs and 95 % CIs) reported in bold text are statistically significant at the 5 % level
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from industry. Our finding that first author but not last
author COIs are associated with publication is intri-
guing. First, there could be differential disclosure and
under-reporting related to their roles related to a par-
ticular abstract [45]. Second, financial support for the
first authors of abstracts could allow time to be spent on
developing a publication, although we may not know the
reason for financial support. For example, was it specif-
ically for writing up the results or a more general sup-
port? More details about the reason for financial support
leading to the COI could have helped us better elucidate
this association. Third, industry could have supported
academic first authors because of the advantages of
working with those viewed as leaders [46–48]. On the
other hand, first authors may be more frequently af-
filiated with academic institutions than last authors
because publishing is a key factor in academic advance-
ment. Finally, we considered whether a greater propor-
tion of first authors than last authors were junior
researchers within academic institutions. Submission of
abstracts is sometimes a means for junior researchers to
attend conferences, and publication in full might be less
of a priority, especially if they move on to other posi-
tions. Because we were unable to examine this possibility
directly (ARVO did not collect author rank/position in-
formation), we calculated the frequencies of first and
last author changes in the publications (assuming
when the abstract’s first author was removed or
moved to a different position, the first author had a
junior rank). The frequencies were similar, however,
making this theory unlikely.
Conclusions
Systematic reviewers should be cautious about including
data from abstracts not associated with full publications.
In our study, conference abstracts were not reliable reflec-
tions of what is reported in the full publication for the
main results. Full publication was not, however, associated
with the statistical significance of results for the abstract’s
main outcome. COIs were associated with the publication
of abstracts only for the abstract’s first author.
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